RT Book, Section
A1 Gruenberg, Katherine
A1 Guglielmo, B. Joseph
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184154258
T1 Sulfones
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184154258
RD 2024/04/16
AB A  number  of  medications  closely  related  to  the  sulfonamides  (eg,  dapsone)  have  been  used  effectively  in  the  long-term  treatment  of  leprosy.  The  clinical  manifestations  of  both  lepromatous  and  tuberculoid  leprosy  can  often  be  suppressed  by  treatment  extending  over  several  years.  At  least  5–30%  of  Mycobacterium  leprae  organisms  are  resistant  to  dapsone,  so  initial  three-drug  treatment  with  rifampin,  dapsone,  and  clofazimine  is  advocated.  Dapsone,  100  mg  daily,  is  effective  therapy  for  mild  to  moderate  Pneumocystis  pneumonia  in  AIDS  when  combined  with  trimethoprim,  15  mg/kg/day  in  three  divided  doses.  At  a  dose  of  50–100  mg  daily  or  100  mg  two  or  three  times  a  week,  it  is  effective  prophylaxis  for  P  jirovecii  infection  and,  when  combined  with  pyrimethamine,  50  mg  per  week,  also  prevents  Toxoplasma  encephalitis  in  HIV-infected  patients.